Sanofi joins Russian Pharmpolis project

Published: 30-Nov-2009

French drugmaker Sanofi-aventis has agreed to participate in a programme that is intended to encourage drug innovation in Russia.


French drugmaker Sanofi-aventis has agreed to participate in a programme that is intended to encourage drug innovation in Russia.

A Sanofi-aventis insulin factory in Russia will be part of the "Pharmpolis Project", which aims to attract drugmakers to Russia and expand the pharmaceutical market in the region.

Sanofi-aventis confirmed its plans with Prominvest, a subsidiary of Rostekhnologii, a Russian state holding company.

"We want to create a situation in which patients suffering from severe conditions, such as diabetes, are diagnosed and treated as early as possible and have access to innovative drugs at affordable prices," said Christopher Viehbacher, ceo of Sanofi-aventis. "The manufacturing of insulin locally will be a major step towards achieving this goal."

  • Companies:
  • Sanofi
See more

You may also like

Regulatory

MHRA's approval of Sanofi's Teplizumab signals a new era in type 1 diabetes management

Read more
Imagine delaying a life-altering chronic illness. Teplizumab offers precious time, potentially freeing eligible individuals and their families from the immediate and overwhelming demands of T1D

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  3. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
  4. New 800 sqm microbiology quality laboratory at Aenova Latina site The project adds approximately 500 square meters of new laboratory space, bringing the total to around 800 square meters, and marks a major milestone in the site’s development
  5. Cytiva and WhiteLab Genomics team up to use AI to accelerate cell line development Collaboration will accelerate stable cell line development in AAV genomic medicine development and ultimately also shorten the development timeline to clinic

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Regulatory

MHRA's approval of Sanofi's Teplizumab signals a new era in type 1 diabetes management

Imagine delaying a life-altering chronic illness. Teplizumab offers precious time, potentially freeing eligible individuals and their families from the immediate and overwhelming demands of T1D
Finance

Sanofi completes acquisition of Blueprint Medicines

Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a commercialised medicine and the expertise of a company specialising in systemic mastocytosis (SM) and other KIT-driven diseases
Distribution

Sanofi ramps up Beyfortus shipping ahead of '25–26 RSV season

Sanofi will boost the availability of the RSV monoclonal antibody vaccine across the US, EU, China and Japan to protect infants from the disease
Research & Development

Sanofi to acquire immunology-focused biopharma company, Blueprint Medicines

The acquisition will allow Sanofi access to Blueprint's rare immunology disease pipeline — a current key focus for the company
Finance

Sanofi completes acquisition of DR-0201

The acquisition bolsters Sanofi’s ambition to become the foremost immunology company and broadens the company’s leading immunology pipeline
Research & Development

Sanofi to acquire neurodegenerative disease biotech, Vigil Neuroscience for $470m

The acquisition will boost Sanofi's neurology pipeline — one of its key disease focus areas
Manufacturing

Sanofi to invest $20bn into US manufacturing capacity following Trump's tariff threats

The company will expand its US pharmaceutical R&D and manufacturing capacity through internal and contract manufacturing investments
Subscribe now